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doi:10.1016/j.jtcvs.2008.02.013Objective: Complexity of mitral valve repair for myxomatous disease has led to low
adoption. We report initial experience with a new ring designed specifically for myx-
omatous disease, the Myxo-ETlogix (Edwards Lifesciences LLC, Irvine, Calif).
Methods: FromMarch 15, 2006, throughNovember 19, 2007, 129 patients underwent
mitral valve surgery for pure myxomatous disease, and 124 valves (96.1%) were re-
paired. The Myxo-ETlogix ring was used in 100 cases and the Physio ring (Edwards)
in 24. The Myxo-ETlogix design includes a 3-dimensional shape to reduce systolic
anterior motion and a larger orifice to accommodate elongated leaflets and decrease
need for sliding plasty. Direct mitral valve measurements were made. Sizing was
based on A2 height, and choice of ring type was based on unresected leaflet heights.
Results: There was no operative mortality or lasting perioperative morbidity. The
Myxo-ETlogix group had taller A2, P1, P2, and P3 leaflet segments than the Physio
group (P # .003). Only 1 sliding plasty was performed for asymmetry in the Myxo-
ETlogix group. Predischarge and follow-up echocardiograms (n 5 338 in 124
patients) disclosed transient nonobstructive chordal systolic anterior motion in 3
echocardiograms in 3 patients. No patients had 21 or greater mitral regurgitation.
At discharge, 5.7% had 11 mitral regurgitation; this proportion was 17.3% at last
follow-up (mean 6.1 6 4.4 months).
Conclusion: In initial experience with theMyxo-ETlogix ring, nonobstructive systolic
anterior motion has been rare and obstructive systolic anterior motion not observed.
Ongoing prospective echocardiographic and clinical studies will elucidate the role
of this etiology-specific ring.
M
itral valve (MV) prolapse is common, occurring in 1% to 2.5% of the pop-
ulation.1 Myxomatous mitral regurgitation (MR) is characterized by elon-
gation and thickening of the valve leaflets with annular and dilatation
prolapse (Carpentier type II).2 Numerous studies have demonstrated that mitral repair
generally gives a more favorable result than does MV replacement, but because of the
complexity of the pathology and therefore the procedure required, it is performed
in fewer than 50% of cases according to data from the United States and Europe.3-6
Furthermore, the considerable interpatient variability has required the surgeon to
approach valve repair as an art, and valve repair has been concentrated such that
a minority of surgeons perform the majority of repairs. Consequently, it has been dif-
ficult for a low- or medium-volume mitral repair surgeon to develop the numerous
skills necessary for successful repair, considering the wide variety of surgical tech-
niques that may be required for complex repairs.
An additional repair problem specific to myxomatous disease is the development
of systolic anterior motion (SAM), which has been reported in 2% to 16% of patients
after mitral repair.7-10 Transient SAM may be seen during first weaning from cardio-
pulmonary bypass and may be easily treated by volume infusion from the pump to
increase the systemic blood pressure (afterload) if the patient is hypotensive and vaso-
dilated and by stopping positive inotropes. More troublesome is persistent SAM,
which may require additional medical or surgical therapy. SAM is precipitated byThe Journal of Thoracic and Cardiovascular Surgery c Volume 136, Number 1 73
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elongated leaflets and may cause left ventricular outflow tract
obstruction and residual or recurrent MR. SAM may be
caused by a short distance between the point of leaflet coap-
tation to the nearest point on the ventricular septum, which
may be seen when the posterior leaflet is too tall or the annu-
loplasty ring placed is too small.7,8 An elongated anterior
leaflet may also contribute to SAM, and numerous techniques
can be used to avoid or eliminate SAM, such as shortening
the anterior leaflet, creating a double orifice (edge-to-edge
approximation), or even myectomy.2,11-16 Reducing the
height of the posterior leaflet (sliding plasty) is the most com-
mon technique.2,10,17 Although some would argue that SAM
may be managed medically with long-term b-blocker therapy
and a low late need for reoperation, persistent SAM may be
associated with continuing MR, and a young patient requir-
ing long-term b-blocker therapy has had an imperfect opera-
tion.18,19 In an age when surgery is being performed early, in
symptom-free patients, this result is less than ideal.1 Ideally,
the repair procedure would avoid SAM altogether and not
require long-term medical management.
We sought to develop a new MV repair ring designed to
accommodate the specific pathologic conditions of myxoma-
tous disease. This etiology-specific ring, the Myxo-ETlogix
(Edwards Lifesciences LLC, Irvine, Calif) ring has a larger
orifice than does a Physio (Edwards Lifesciences) ring
(which is based on normal anatomy) to accommodate the
elongated leaflets. It also has a 3-dimensional shape that
moves the coaptation point away from the septum (increasing
the distance between the point of leaflet coaptation to the
nearest point on the ventricular septum), thereby reducing
the risk of SAM.8,14 Because this etiology-specific ring has
a larger orifice, a secondary advantage would be that exten-
sive leaflet reconstruction to reduce the size of the leaflets
back to ‘‘normal’’ (sliding plasty) would not be needed, or
at least would be needed much less frequently. This would re-
duce the complexity of myxomatous valve repair and ideally
make it more generalizable. Furthermore, the larger orifice
leads to a low or normal gradient. This is the first report of
the concepts behind the new Myxo-ETlogix, the impact
that it had on our use of other mitral repair rings and tech-
niques, and the initial clinical results.
Materials and Methods
Patient Characteristics
Patient information and follow-up data were obtained from the pro-
spectively maintained cardiac surgery outcomes registry of the74 The Journal of Thoracic and Cardiovascular Surgery c July 2Bluhm Cardiovascular Institute, which was approved by the North-
western University Institutional Review Board for use in research.
The study ran from the date of first use of Myxo-ETlogix (March
15, 2006) until the date of 100th Myxo-ETlogix implant (November
19, 2007). For the purposes of this study, we analyzed only those
patients with MR caused by isolated myxomatous degenerative
MVdisease (n5 129). The diagnosis ofmyxomatous diseasewas de-
termined by echocardiographic and surgical findings of elongated
MV leaflets with prolapse (type II). Patients were excluded if they
had rheumatic valve disease, ischemic valve disease, cardiomyopa-
thy, endocarditis, or mixed pathology. Among the 129 myxomatous
MR cases, MV repair was performed in 124 patients (96.1%), and
MV replacementwas performed in 5 patients (3.9%). These 5 patients
had ages of 65, 72, 74, 78, and 84 years, and all had annular and leaflet
calcification. Patients included in this analysis were operated on by
two surgeons at a single institution,NorthwesternMemorialHospital.
In the repair group, 100 patients received the Myxo-ETlogix an-
nuloplasty ring, which is a Food and Drug Administration–approved
ring for patients undergoing MV repair. During the same period, the
Carpentier–Edwards Physio ring was used to repair 24 valves in pa-
tients with myxomatous MV disease. Thus 80.6% of the patients
with myxomatous disease underwent repair with the Myxo-ETlogix
ring, and 19.4% underwent repair with a Physio ring. According to
our practice, all patients in the group were prospectively followed up
by a specific valve nurse who was available to answer patient ques-
tions, arrange follow-up visits, and facilitate entry into prospective
3-dimensional echocardiographic and other imaging studies. The
characteristics of the patients who received the Myxo-ETlogix
ring are compared with those of the patients who received a Physio
ring in Table 1. Overall, the age of the patients was 57 6 13 years,
and the Myxo-ETlogix patients were younger (P 5 .047). The
Myxo-ETlogix patients had more MR (97% with 41, P , .001).
Other significant differences between the groups included smaller
body mass index and more white patients in the Myxo-ETlogix
group (patient self-report), whereas patients in the Physio group
were more likely to have chronic obstructive pulmonary disease.
The 5 patients who underwent MV replacement were significantly
older than the 124 repair patients (P, .001), and their operative find-
ings precluded safe, durableMV repair. All these patients underwent
valve replacement with a bioprosthetic bovine pericardial valve. In
keeping with the trend toward early repair in patients with myxoma-
tousMVdisease, most of the patients in the repair groupwere inNew
York Heart Association functional class I or II (81.4%).
Characteristics of the Myxo-ETlogix Ring
TheMyxo-ETlogix ring was designed as a complete annular remod-
eling ring with etiology-specific variations from the Physio ring
(Figure 1).20 The anteroposterior dimension of the ring was
increased 29% to accommodate elongated myxomatous leaflets.
Depending on the exact size of the ring, this led to an increase in
anteroposterior diameter of 5 to 8 mm, designed to correspond to
typical reduction in posterior leaflet height in patients who undergo
sliding plasty. Rather than the surgeon performing extensive recon-
struction to reduce the height of the posterior leaflet by 5 to 8 mm,
instead the ring pulls the posterior leaflet down by a corresponding
amount. This also creates a 16% increase in the total orifice area for
the Myxo-ETlogix ring. The largest anteroposterior diameter of
a size 40 Physio ring is 27.2 mm, which corresponds most closely
to a size 32Myxo-ETlogix ring (28.0mm). A size 40Myxo-ETlogix008
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Total (N 5 124) Physio (n 5 24) Myxo-ETlogix (n 5 100) P value
Age (y) .047*
Mean 6 SD 57.4 6 13.4 62.2 6 12.1 56.2 6 13.5
Range 22–85 41–81 22–85
Male (No.) 76 (61.2%) 14 (58.3%) 62 (62.0%) NS
Body mass index (kg/m2) .006y
Mean 6 SD 25.4 6 4.5 27.6 6 3.9 24.9 6 4.5
Range 15.1–39.5 20.2–34.2 15.1–39.5
White race (No.) 103 (83.1%) 16 (66.7%) 87 (87.0%) .017
Previous cardiac surgery (No.) 1 (0.8%) 0 (0.0%) 1 (1.0%) NS
Comorbidities (No.)
Previous myocardial infarction 2 (1.6%) 1 (4.2%) 1 (1.0%) NS
Congestive heart failure 16 (12.9%) 5 (20.8%) 11 (11.0%) NS
Coronary artery disease 19 (15.3%) 4 (16.7%) 15 (15.0%) NS
Diabetes 3 (2.4%) 0 (0.0%) 3 (3.0%) NS
Hypertension (systemic) 48 (38.7%) 13 (54.2%) 35 (35.0%) .083
Hypertension (pulmonary) 65 (52.9%) 13 (54.2%) 52 (52.0%) NS
Renal failure 0 (0.0%) 0 (0.0) 0 (0.0) NS
Chronic obstructive pulmonary disease 8 (6.5%) 4 (16.7%) 4 (4.0%) .045z
Hyperlipidemia 40 (32.3%) 9 (37.5%) 31 (31.0%) NS
Atrial fibrillation or flutter 26 (21.0%) 7 (29.2%) 19 (19.0%) NS
New York Heart Association functional class (No.) NS
I 35 (28.2%) 4 (16.7%) 31 (31.0%)
II 66 (53.2%) 13 (54.2%) 53 (53.0%)
III–IV 23 (18.6%) 7 (29.2%) 16 (16.0%)
Prolapse (No.) NS
Anterior 8 (6.5%) 2 (8.7%) 6 (6.0%)
Posterior 83 (67.5%) 19 (82.6%) 64 (64.0%)
Anterior and posterior 32 (26.0%) 2 (8.7%) 30 (30.0%)
Preoperative echocardiographic mitral
regurgitation (No.)
,.001
21 2 (1.6%) 2 (8.3%) 0 (0.0%)
31 7 (5.7%) 4 (16.7%) 3 (3.0%)
41 115 (92.7%) 18 (75.0%) 97 (97.0%)
LV ejection fraction (%) NS
Mean 6 SD 59.4% 6 7.5% 60.7% 6 7.0% 59.1% 6 7.6%
Range 35%–80% 50%–80% 35%–75%
LV end-systolic dimension (cm) NS
Mean 6 SD 3.6 6 0.6 3.6 6 0.6 3.6 6 0.6
Range 2.1–5.1 2.3–4.4 2.1–5.1
LV end-diastolic dimension (cm) NS
Mean 6 SD 5.5 6 0.7 5.5 6 0.6 5.5 6 0.7
Range 3.9–7.1 4.3–6.5 3.9–7.1
NS, not significant (P . .20); LV, left ventricular. *Squared transformation. yNatural log transformation. zFisher exact test.ring has an anteroposterior diameter of 35.0 mm. The Myxo-ETlo-
gix ring was only available in sizes 26 through 36 until mid Novem-
ber 2006, when sizes 38 and 40 became available but sizes 26 and 28
became unavailable. This shortage was due to production of a lim-
ited quantity of early rings.
In addition to accommodating the larger leaflets, the Myxo-ET-
logix ring was designed to move the coaptation point down, and also
away from the septum, by means of a 4-mm shape change centered
at the P2 region, pulling the ring into the left atrium (Figure 1) and
resulting in an increase in the distance between the point of leaflet
coaptation to the nearest point on the ventricular septum. The netThe Journal of Thoeffect of these two changes is to pull the coaptation point down
and away from the septum.
Operative Techniques
Operative techniques were largely based on Carpentier’s time-tested
concepts of resection of the prolapsing segment, chordal transfer if
necessary, leaflet reconstruction, and complete remodeling annulo-
plasty ring.3,20 The Myxo-ETlogix ring was used for patients with
elongated anterior leaflets or tall remaining posterior leaflet segments
after resection. If the remaining posterior and anterior leaflets were
normal after resection, then a Physio ringwas used.Repair techniquesracic and Cardiovascular Surgery c Volume 136, Number 1 75
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CDFigure 1. Myxo-ETlogix ring designed for pa-
tients with leaflet elongation historically treated
with sliding plasty with risk of systolic anterior
motion. Ring has longer anteroposterior diameter
(typically 6 mm) to accommodate larger leaflets,
corresponding to typical posterior leaflet height
reduction from sliding plasty. P2 segment of ring
has 4-mm displacement into annulus. Net effect
of these two changes moves coaptation point
down and away from septum, reducing risk of
systolic anterior motion.for both groups included leaflet resection, chordal transfer, commis-
suroplasty, and ring annuloplasty. No artificial chords were used in
any patients.Before theMyxo-ETlogix ringwas available, sliding an-
nuloplasty was performed in 38% of cases of myxomatous disease
(according to our database) when the remaining posterior segments
were longer than 20 mm by visual inspection (not by direct measure-
ment, whichwas not yet available) and sometimeswhen the posterior
leaflet was shorter than 20 mm but there was a wide resection.
Concomitant cardiac surgical procedures (Table 2) included
a maze procedure in 31 patients (25%), tricuspid valve annuloplasty
in 12 patients (9.7%), coronary artery bypass grafting in 17 patients
(13.7%), and aortic valve replacement in 3 patients (2.4%). There
was no difference in concomitant procedures between the Physio
and Myxo-ETlogix groups, but the ring size used in the Myxo-ET-
logix group was larger (P 5 .001). The 1 patient (in the Myxo-ET-
logix group) who underwent sliding plasty had an unresected
remnant P2 height of 27 mm and a P3 height of 16 mm. Because
of the extensive size discrepancy and a wide resection (22 mm),
the height of the remaining P2 was reduced with a short sliding
plasty. A second pump run was performed in 2 cases (1.6%) because
of residual MR (11–21), with conversion from repair to replace-
ment in an 84-year-old patient and successful additional leaflet
repair in another patient.
Direct MV Measurements and Choice of Myxo-
ETlogix Versus Physio Ring
Direct measurements of the MV were taken with a custom-designed
set of measuring calipers. These distance measurements included
commissure-to-commissure, trigone-to-trigone, and heights of the
leaflet at P1, P2, P3, and A2 segments (Figure 2). Other measure-
ments included width of the resected segment, width of the annulus
after compression sutures, height of the middle segment of the pos-
terior leaflet after reconstruction when applicable, and overlaps at
P1, P2, P3, A1, A2, and A3. The results of these measurements
are depicted in Figure 2. Table 3 compares the measures in patients
with Myxo-ETlogix rings with those of patients with Physio rings.
Measurements were available for 98 of 100 patients in the Myxo-
ETlogix group and 22 of 24 patients in the Physio group.
Ring size was chosen according to A2 height. The measurement
was referenced to a chart of the anteroposterior diameter of Myxo-76 The Journal of Thoracic and Cardiovascular Surgery c JulyETlogix and Physio rings. Ring size was true sized to A2 height
in most cases. Occasionally, a largerMyxo-ETlogix ring was chosen
because of an unusually tall (.20 mm) posterior leaflet, a smaller
Myxo-ETlogix ring was chosen if there was a short posterior leaflet
(,12mm), or another size was chosen if the closest ring size was not
available. Other measurements or judgments (commissure-to-com-
missure, trigone-to-trigone, anterior leaflet surface area) were not
used for sizing.
The Physio ring was used for the subset of patients who had what
Carpentier classifies as ‘‘fibroelastic deficiency.’’21 This group
tended to be older, with associated comorbidities such as hyperten-
sion and chronic obstructive pulmonary disease, and the pathologic
characteristics typically consisted of ruptured chords at the P2 seg-
ment with normal lengths of P1, P3, and A2. The pathology at P2
was resected, and the remaining valve leaflet lengths were therefore
normal, so the Physio ring was chosen as a design based on normal
valve anatomy.10 Patients who received a Myxo-ETlogix ring con-
sisted of those with Barlow disease and those with lengthening of
unresected segments of the leaflet, the anterior leaflet, or both.
Most patients did not fall into two distinct categories (Barlow dis-
ease vs fibroelastic deficiency) and instead had more intermediate
leaflet length, as depicted in Figure 2.
Echocardiographic Techniques
MR was assessed as follows: none or trivial, 0; mild, 11; moderate,
21; moderate to severe, 31; and severe, 41. Nonobstructive
(chordal) SAM was defined as anterior motion of the MV or sub-
valvular apparatus without an elevation of the peak velocity or
a late peaking velocity profile in the Doppler waveforms in the
left ventricle or left ventricular outflow tract. Echocardiography
was performed in 100% of patients intraoperatively, at discharge,
and, according to our usual practice, at approximately 1 month
and between 3 and 6 months after surgery, annually, and any other
time as clinically indicated.
Statistical Analysis
Demographic and clinical patient characteristics in the Physio and
Myxo-ETlogix groups were compared with t tests for continuous
variables and c2 tests for categorical variables. Group differences
in intraoperative variables were evaluated with the same2008
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Total (N 5 124) Physio (n 5 24) Myxo-ETlogix (n 5 100) P value
Ring size (mm) .001
Mean 6 SD 33.0 6 3.4 31.1 6 2.6 33.5 6 3.4
Range 26–40 26–36 26–40
Resection (No.) 110 (88.7%) 20 (83.3%) 90 (90.0%) NS
Width of resection (mm) ,.001
Mean 6 SD 15.5 6 6.4 11.3 6 3.5 16.6 6 6.5
Range 7–36 7–20 7–36
Sliding plasty (No.) 0 (0.8)% 0 (0.0%) 1 (1.0%) NS
Chordal transfer (No.) 20 (16.1%) 1 (4.2%) 19 (19.0%) .119*
Crossclamp time (min) .195y
Mean 6 SD 88.1 6 22.7 83.5 6 24.1 89.2 6 22.3
Range 52–169 52–138 55–169
Cardiopulmonary bypass time (min) NS
Mean 6 SD 104.7 6 26.1 101.0 6 26.5 105.6 6 26.0
Range 67–190 67–159 67–190
Commissuroplasty (No.) 7 (5.7%) 0 (0.00%) 7 (7.0%) NS
Concomitant procedures (No.)
Coronary artery bypass grafting 17 (13.7%) 3 (12.5%) 14 (14.0%) NS
Atrial valve replacement 3 (2.4%) 0 (0.00%) 3 (3.0%) NS
Tricuspid valve annuloplasty 12 (9.7%) 1 (4.2%) 11 (11.0%) NS
Maze 31 (25.0%) 8 (33.3%) 23 (23.0%) NS
Postoperative
Mortality, infection, myocardial infarction,
or acute renal failure (No.)
0 (0.0%) 0 (0.0%) 0 (0.0%) NS
Reoperation for bleeding (No.) 1 (0.8%) 0 (0.0%) 1 (1.0%) NS
Cerebrovascular accident (No.) 1 (0.8%) 0 (0.0%) 1 (1.0%) NS
Hospital stay (d) NS
Mean 6 SD 5.8 6 2.9 6.0 6 2.6 5.6 6 2.9
Range 3–24 4–15 3–24
Intraoperative echocardiography
Mitral regurgitation (No.) NS
0 121 (97.6%) 23 (95.8%) 98 (98.0%)
11 3 (2.4%) 1 (4.2%) 2 (2.0%)
Mean gradient (mm Hg) NS
Mean 6 SD 3.1 6 1.5 3.3 6 1.9 3.0 6 1.4
Range 0.6–10.0 1.4–10.0 0.6–9.0
Predischarge echocardiography
Mitral regurgitation (No.) NS
0 115 (92.7%) 23 (95.8%) 92 (93.9%)
11 7 (5.7%) 1 (4.2%) 6 (6.1%)
Mean gradient (mm Hg) .134y
Mean 6 SD 3.3 6 1.4 3.7 6 1.7 3.2 6 1.4
Range 1.2–8.6 1.5–8.0 1.2–8.6
NS, Not significant. *Fisher exact test. yNatural log transformation.methodology. Continuous variables were appropriately transformed
if a better approximation of normal distribution could be achieved.
Fisher exact test was used for comparisons of categorical variables
with a minimum cell count of 5 or less.
Results
Postoperative complications were low, with no deaths, no in-
fections, no perioperative infarctions, 1 reoperation for bleed-
ing (0.8%), and 1 stroke on postoperative day 3 from atrialThe Journal of Thofibrillation that resolved before discharge. Follow-up was
100% complete, and there were no late deaths.
Predischarge and follow-up echocardiograms totaled 338.
No MR or trivial MR was present at discharge in 92.7% of
patients, and 11 was present in 5.7% (Table 2). Mean
gradient at discharge showed a trend toward being higher
in the Physio group (3.7 6 1.7 mm Hg vs 3.2 6 1.4 mm
Hg, P 5 .134, natural log transformation to normalize the
data). At most recent follow-up (mean 6.1 6 4.4 months)racic and Cardiovascular Surgery c Volume 136, Number 1 77
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ments documenting elongated leaflets in bell-shaped frequency curve. In particular, A2 height was very elongated;
this was used to choose appropriate ring type (Physio ring vs Myxo-ETlogix ring) and ring size.11 MR was present in the Physio group in 1 patient (10%)
and in the Myxo-ETlogix group in 16 patients (18%, differ-
ences from baseline and between groups not significant).
There was no significant difference between MR at discharge
and last follow-up. No patients had 21 or greater MR.
After surgery, no obstructive SAM was seen, and nonob-
structive chordal SAM was inconsistently seen in 3 patients.
In 1 patient (with a 32-mm Myxo-ETlogix valve), SAM was
first detected 14 days after discharge, but subsequent echo-
cardiograms on days 82, 214, and 397 had negative results.
In a second patient (with a 36-mm Myxo-ETlogix valve),
there was no SAM early (predischarge or day 12 after dis-
charge), SAM was recorded on day 160 after discharge,
and at 1-year follow-up there was no SAM. In a third patient
(with a 34-mm Physio ring), discharge echocardiography
showed chordal SAM; this patient has not yet returned for
follow-up. Transient intraoperative SAM shortly after wean-
ing from bypass was uncommon (3 patients), depended on
volume status and blood pressure, and never required a sec-78 The Journal of Thoracic and Cardiovascular Surgery c Julyond pump run or revision. One patient (with a 28-mm
Myxo-ETlogix valve with commissuroplasty) had an early
uneventful course after repair, with a low gradient (3.5 mm
Hg), but had an intense, generalized inflammatory reaction,
including both mitral leaflets, and required reoperative MV
replacement for mitral stenosis 13 months after repair. Table
2 summarizes operative results for both groups.
Discussion
Overall, in an age of early repair for myxomatous disease, our
results demonstrated a safe operation with low morbidity,
a high rate of repair (96%), and excellent early results with
little residual or recurrent MR (none at least 21). We have
found clinical benefit in precise anatomic measurement of
the pathologic tissue, and these data drive our choice of
ring size and type of ring prosthesis. This has led to predict-
able coaptation of the leaflets, without rings or residual leaflet
heights we considered too small or too big. Our data indicate
that although some patients’ leaflets fall into the extremes of2008
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Measurement (mm) Total Physio (n 5 22) Myxo-ETlogix (n 5 98) P value
A2 ,.001
Mean 6 SD 27.9 6 4.9 23.7 6 5.2 28.9 6 4.3
Range 15-41 17-34 15-41
P1 ,.001
Mean 6 SD 13.6 6 4.3 10.6 6 2.9 14.3 6 4.3
Range 6-27 6-20 6-27
P2 .003
Mean 6 SD 21.9 6 5.1 19.0 6 4.6 22.5 6 5.0
Range 7-34 9-30 7-34
P-middle* ,.001
Mean 6 SD 14.6 6 2.9 12.3 6 1.9 15.1 6 2.8
Range 8-23 10-16 8-23
P3 ,.001
Mean 6 SD 15.1 6 3.8 12.5 6 2.6 15.7 6 3.8
Range 6-24 8-18 6-24
Cusp-to cusp .007
Mean 6 SD 38.1 6 6.0 35.0 6 4.3 38.8 6 6.2
Range 27-51 27-45 27-51
Trigone-to-trigone .023
Mean 6 SD 24.6 6 4.2 22.8 6 3.4 25.0 6 4.3
Range 14-36 16-28 14-36
P2 overlap .003
Mean 6 SD 6.5 6 1.9 5.4 6 1.4 6.8 6 1.9
Range 2-13 4-9 2-13
A2 overlap .070
Mean 6 SD 5.7 6 1.9 5.0 6 1.6 5.8 6 1.9
Range 2-11 3-9 2-11
*P-middle is the height of the leaflet after P2 resection and reconstruction.Barlow disease versus fibroelastic deficiency, most patients’
leaflet lengths fall somewhere between these extremes.
Although an artistic, creative approach to complex valve
problems with many different techniques is still valuable,
we hope to move toward a more standardized, generalizable,
reproducible repair that will lead to higher repair rates. Our
current approach includes three steps: (1) trapezoidal resec-
tion (mean 15.5 6 6.4 mm) of prolapsing posterior leaflet
segments with chordal transfer to extensive anterior prolaps-
ing segments if needed, (2) ring choice and sizing that is
based on A2 and remaining posterior leaflet heights, and
(3) complete remodeling annuloplasty with a Physio ring
for normal remaining leaflets or with a Myxo-ETlogix ring
for elongated leaflets. Although sliding plasty (and other
complex techniques) should not be forgotten, in our institu-
tion we reduced the use of sliding plasty from 38% before
this series to less than 1% in this experience. After recon-
struction, the ratio of A2 height to posterior leaflet was 1.9
in both groups, which is thought to be optimal. Others
routinely use resection without sliding plasty, but SAM
does appear to be more common in those series than in
ours (2.4% transient nonobstructive SAM and SAM without
left ventricular outflow tract obstruction).18,22The Journal of ThorQuantitative data, other than from echocardiograms, have
been hard to find in mitral repair series. Use of the Adams
‘‘ink test’’ and direct measurement of valve segments should
help standardize our results and make it easier to compare re-
sults from different series.23-25 All these points are important,
because we now see symptom-free patients for whom the
guidelines recommend repair at experienced centers if there
is a greater than 90% chance of repair without residual
MR.1,24,25
Large annuloplasty rings have been recommended for pa-
tients with Barlow disease.7We agree that this is an important
consideration, and more practical than bileaflet resection or
reconstruction to reduce leaflet height. The new Myxo-ETlo-
gix ring, designed for these patients, is significantly larger
than existing commercial remodeling rings. Barlow disease
is not a distinct entity in most cases, however, and even
histologic studies have shown a large group of disorders
intermediate between Barlow disease and fibroelastic
deficiency.21 Whereas some surgeons may describe Barlow
disease in 1% of patients, others may use that term to describe
50% of their patients with degenerative disease. Furthermore,
our data show that some patients may have an elongated A2
segment but normal posterior segments, or vice versa. Theacic and Cardiovascular Surgery c Volume 136, Number 1 79
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CDchoice of a large ring thus is variable by surgeon. Although the
average A2 height in our series (29 mm) corresponds most
closely to a 34 Myxo-ETlogix ring, larger than the largest
Physio ring (27 mm), we commonly used smaller Myxo-
ETlogix rings instead of large Physio rings because of the
perceivedbenefit of the4-mmP2displacementwith theMyxo-
ETlogix ring to reduce the risk of SAM. Whether it is the P2
displacement or the large size of the Myxo-ETlogix ring that
accounts for our low incidence of SAM is not yet clear.
Study Limitations
This was a nonrandomized study of the initial use of a new
commercially available ring, but not all ring sizes were avail-
able during the study period. The inventor of the ring was the
surgeon in the vast majority of cases, and we attempted to re-
duce this bias with direct quantitative measurements and
standard echocardiographic reporting. The data in all tables
and figures therefore represent unbiased measurements and
clinical results. A randomized trial is certainly feasible but
would be best performed at another institution, albeit with
experienced surgeons.
In summary, a new ring was introduced with a change in
our clinical practice. The result was simpler MV repair pro-
cedures, rare nonobstructive SAM, and excellent clinical
and echocardiographic results. Further confirmation at other
centers is pending, and late echocardiographic follow-up is
ongoing.
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Discussion
Dr Aidan A. Raney (Newport Beach, Calif). I enjoyed this presen-
tation very much. Dr McCarthy is making a major contribution. As
he mentioned, the repairability rate of valves in this country is in the008
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CD40% to 50% range. However, if the most complex valves with ex-
cessive tissue are included, the overall repairability rate is probably
going to be significantly lower, maybe in the 30% range. This device
is a tremendous advance. Not only does it simplify the procedure but
it also reduces the risk of SAM.
Whenwe looked at our series of over 200 patients about 11/2 years
ago, we also had about a 5% incidence of SAM that required a sec-
ond pump run and correction.
I have a few questions for you. In your series, are you repairing
all the myxomatous valves with the Myxo-ETlogix ring or do you
have a sense of certain valve characteristics that would preclude
using this device?
Dr McCarthy. Right now, we look at the leaflet and annulus
size. In the majority of these patients with myxomatous leaflets,
something is elongated. The valves do not always fall into that cat-
egory of fibroelastic deficiency, so that it may be an elongated ante-
rior leaflet but not a very elongated posterior, or the other way
around. I use the Physio ring when the remaining valve is normal:
the anterior leaflet, P1 and P3, are normal, and we have resected
the abnormal part, which is usually a flail involving P2.
Dr Raney. Do you think that there is less modification of the
annulus with this device, that is, without quadrangular resection and
a plication of the posterior annulus? Because sizing can be a prob-
lem, do you think that transesophageal echocardiography before
the repair will provide a good indication of what size of a Myxo-
ETlogix ring to use?
Dr McCarthy. We are collecting a big database on our MV
repairs, and we are also going to correlate it with what echocardiog-
raphy measures. So far, it looks very good. When we measure A2 at
29 mm, the echocardiographer measures it at roughly the same. We
hope to get to a point where the echocardiographer can identify theThe Journal of Thoheight of the anterior and posterior leaflets and we can then prescribe
the right sized ring.
Dr Raney. We have used this ring now in 8 cases, and I have
been very impressed with the efficacy and the efficiency of the ring.
DrMichaelMack (Dallas, Tex).DrMcCarthy, do you have any
experience using this ring with artificial chords and does that make
sense?
DrMcCarthy. I think it makes sense. I do not really use artificial
chords very much. I am still pretty classic and I do chordal transfer.
However, some surgeons are using artificial chords with the ring. If
artificial chords are used on the posterior leaflet where there is an
elongated P2 segment that is not being replaced, I think this would
make sense, because otherwise, as you could see from the AP diam-
eter, a 40-mm Physio ring is not nearly big enough for that group of
patients.
Dr Mack. Is this ring generally available?
Dr McCarthy. It is in the United States now.
Dr Jen-Ping Chang (Kaohsiung, Taiwan). We all know that
Professor Carpentier repairs the Barlow valves by banding the septal
portion of the classic ring anteriorly, and we know your ring is just
like bending the posterior portion of the ring posteriorly. What is the
difference between the anterior displacement and the posterior
displacement of this ring?
Dr McCarthy. The anterior displacement that Dr Carpentier
does periodically is variable: he could bend it just a little bit or he
could bend it quite a bit. It seemed to us most of the reduction should
be more posterior rather than anterior, and so when we designed the
ring, that is where we put it. Also, remember on the classic ring when
Dr. Carpentier bends it that way, that is the only place he can bend it
because that is where the break is in the ring. So it is the only part
that is practical.racic and Cardiovascular Surgery c Volume 136, Number 1 81
